Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-12
DOI
10.1007/s12325-021-01710-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
- (2020) W. Timothy Garvey et al. DIABETES CARE
- Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
- (2020) Thomas A. Wadden et al. Obesity
- Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
- (2020) Tina K. Thethi et al. DIABETES OBESITY & METABOLISM
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- (2020) Robert F. Kushner et al. Obesity
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
- (2020) Martin Friedrichsen et al. DIABETES OBESITY & METABOLISM
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
- (2019) V. R Aroda et al. DIABETES & METABOLISM
- Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study
- (2019) Richard E. Pratley et al. DIABETES OBESITY & METABOLISM
- Cardiovascular risk and obesity
- (2019) C. Cercato et al. Diabetology & Metabolic Syndrome
- GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones and Regional Body Fat Stores in Adults with Obesity
- (2019) Hoda Kadouh et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Incretin hormones: Their role in health and disease
- (2018) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- PROVIDER PRACTICE HABITS AND BARRIERS TO CARE IN OBESITY MANAGEMENT IN A LARGE MULTICENTER HEALTH SYSTEM
- (2018) Rebecca Simon et al. Endocrine Practice
- Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
- (2018) Greer Waldrop et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Maintenance of Lost Weight and Long-Term Management of Obesity
- (2018) Kevin D. Hall et al. MEDICAL CLINICS OF NORTH AMERICA
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study
- (2017) Lee M. Kaplan et al. Obesity
- Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial
- (2017) Malin Nylander et al. REPRODUCTIVE BIOMEDICINE ONLINE
- Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity
- (2016) Faidon Magkos et al. Cell Metabolism
- Obesity and Cardiovascular Disease
- (2016) Francisco B. Ortega et al. CIRCULATION RESEARCH
- Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data
- (2016) Michael E. Trautmann et al. CLINICAL THERAPEUTICS
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
- (2016) Olivia M. Farr et al. DIABETOLOGIA
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Central nervous system regulation of eating: Insights from human brain imaging
- (2016) Olivia M. Farr et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s
- (2016) Catherine E. Thomas et al. Obesity
- Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From aDiabetes CareEditors’ Expert Forum
- (2015) William T. Cefalu et al. DIABETES CARE
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- European Guidelines for Obesity Management in Adults
- (2015) Volkan Yumuk et al. Obesity Facts
- The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA
- (2015) Charles Baum et al. PHARMACOECONOMICS
- Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
- (2014) E W Iepsen et al. INTERNATIONAL JOURNAL OF OBESITY
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
- (2014) Stephen C L Gough et al. Lancet Diabetes & Endocrinology
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
- (2013) M E J Lean et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Long-term Drug Treatment for Obesity
- (2013) Susan Z. Yanovski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
- (2011) R. R. Wing et al. DIABETES CARE
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Long-Term Persistence of Hormonal Adaptations to Weight Loss
- (2011) Priya Sumithran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity
- (2010) J. G. Kang et al. DIABETES OBESITY & METABOLISM
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- Management of gallstones and gallbladder disease in patients undergoing gastric bypass
- (2010) Bernabé M Quesada WORLD JOURNAL OF GASTROENTEROLOGY
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
- (2009) Prospective Studies Collaboration LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search